<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karavasilis, V.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Gogas, H.</style></author><author><style face="normal" font="default" size="100%">Kouvatseas, G.</style></author><author><style face="normal" font="default" size="100%">Pentheroudakis, G.</style></author><author><style face="normal" font="default" size="100%">Koutras, A.</style></author><author><style face="normal" font="default" size="100%">Christodoulou, C.</style></author><author><style face="normal" font="default" size="100%">Bafaloukos, D.</style></author><author><style face="normal" font="default" size="100%">Samantas, E.</style></author><author><style face="normal" font="default" size="100%">Pisanidis, N.</style></author><author><style face="normal" font="default" size="100%">Papakostas, P.</style></author><author><style face="normal" font="default" size="100%">Aravantinos, G.</style></author><author><style face="normal" font="default" size="100%">Karanikiotis, C.</style></author><author><style face="normal" font="default" size="100%">Kosmidis, P.</style></author><author><style face="normal" font="default" size="100%">Pectasides, D.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Breast Cancer</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Clinical benefit</style></keyword><keyword><style  face="normal" font="default" size="100%">Competing risks analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Elderly patients</style></keyword><keyword><style  face="normal" font="default" size="100%">feasibility</style></keyword><keyword><style  face="normal" font="default" size="100%">Toxicity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953775688&amp;doi=10.1016%2fj.clbc.2015.12.001&amp;partnerID=40&amp;md5=8ade2bc4c35e7f13a2e1b9bb7ebd63d6</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">291 - 298.e3</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Micro-Abstract We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy in women &gt;65 years of age with early breast cancer. Elderly breast cancer patients derive clinical benefit comparable with that of younger patients, mainly at the cost of increased risk of hematological toxicity. © 2015 Elsevier Inc.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Cited By :1Export Date: 21 February 2017</style></notes></record></records></xml>